Efficacy and Tolerability of Clozapine versus Quetiapine in Treatment-resistant Schizophrenia

Mitesh Kumar, B. S. Chavan, Ajeet Sidana, Subhash Das

ABSTRACT

**Objective:** To compare the efficacy and tolerability of clozapine and quetiapine in patients with treatment-resistant schizophrenia (TRS).

**Patients and Methods:** In this prospective, randomized, open label study of 14 weeks, 53 patients with schizophrenia diagnosed as per ICD-10 and fulfilling the modified version of Conley and Kelly’s criteria of TRS were randomly assigned to receive clozapine or quetiapine as per a computer-generated random table. After 2-weeks of dose-titration phase, doses were fixed at minimum therapeutic dose and subsequently adjusted according to the clinical improvement. All patients received dosage of respective drug in therapeutic range. 13 patients were lost to follow up. Treatment efficacy and side effects were evaluated with standardized rating scales.

**Results:** Clozapine group (reduction in total score: mean = 14.45, SD = 10.39) had significantly greater reductions (P = 0.004; CI = 3.541-17.059) in the Positive and Negative Syndrome Scale (PANSS) total score, PANSS positive subscale and PANSS general psychopathology subscale at 14 weeks in comparison to the quetiapine group (reduction in total score: mean = 4.15, SD = 10.71). Significant reduction in PANSS negative subscale was seen with both drugs but no significant difference was present between the two drugs. At 14 weeks, 30% patients in clozapine group and 15% patients in quetiapine group showed response. Clozapine led to significantly greater side effects (P<0.001, CI=2.241-6.059) on Glassgow Antipsychotic Side-effect Scale (GASS) than quetiapine.

**Conclusions:** Clozapine was found to be more efficacious than quetiapine in patients with TRS but was associated with greater side effects. Both the drugs were found to be equally effective in reducing the negative symptoms.

**Key words:** Clozapine, quetiapine, treatment-resistant schizophrenia

INTRODUCTION

Schizophrenia carries a high degree of disability, which accounts for 0.5% of the disability-adjusted life years. Antipsychotic is the main-stay of treatment for people with schizophrenia, and yet approximately one-fifth to one-third of patients with this disorder are resistant to drug treatment. Clozapine has been found to be effective in treatment-resistant schizophrenia (TRS) and it was approved for TRS by the Food and Drug Administration in 1989. However, approximately 40%–70% of...
neuroleptic-resistant patients with schizophrenia are nonresponders even to clozapine.[3] Moreover, with clozapine exists a risk of agranulocytosis.[3,4] Quetiapine, with structural analogy to clozapine, but with molecular discrepancies explaining the lack of agranulocytosis risk[5] seems to be an alternative in TRS. There are a few studies showing the efficacy of quetiapine in the treatment of schizophrenia resistant to previous antipsychotics,[7] but the findings have not been replicated in other studies, and there is a dearth of such studies carried out on the Indian population. Thus to look at an alternative treatment regimen for TRS, this study was a logical outcome where the authors set out to address some unanswered queries.

**METHODS**

Patients who came to the Department of Psychiatry of Government Medical College and Hospital (GMCH), Chandigarh, India were considered for the study. They were 18–65 years, met the International Classification of Diseases, Tenth Revision-Diagnostic Criteria for Research criteria for schizophrenia, gave informed consent, were accompanied by the reliable informant and were enrolled in the study from December 2013 to June 2015.

For the study, modified version of Conley and Kelly’s criteria[2] of TRS was used, which is defined as, “No clinical response with two different antipsychotics used separately in the dose range of 400-600 mg of chlorpromazine per day or equivalents for 6 weeks; no period of good social or occupational functioning at least in last 1 year, and a minimum clinical global impressions (CGIs) scale rating of 4 (moderately ill); Brief Psychiatric Rating Scale (BPRS) total score >45, and a score of >4 on 2 out of 4 positive items.”

Patients with a history of treatment with clozapine and/or quetiapine in the past, having seizure disorder, heart conduction defects, history of agranulocytosis or total lymphocyte count <3500/cubic mm, diabetes mellitus, neurological disorders, head injury, movement disorder, lactating or pregnant women, comorbid substance dependence except nicotine and caffeine, subnormal intelligence and late-onset schizophrenia (after 45 years) were excluded.

This was a comparative, open-label, prospective interventional study. The patients were randomly assigned into two groups as: Group A (clozapine group) or Group B (quetiapine group) as per a computer-generated random table with an aim to recruit a minimum of twenty patients in each group and were followed up for 14 weeks after treatment initiation. The trial was registered with Clinical Trial Registry, India (CTRI Registration number CTRI/2016/02/006660).

The principles enunciated in the Declaration of Helsinki[9] and Indian Council of Medical Research[10] was complied with and the study was approved by the ethical review committee of the institution.

**Intervention**

After recruitment, patients who were on antipsychotics were given a drug-free/washout period (1 week for oral; 1 month for long-acting depot preparation). The patients were randomly allocated to either of the Group A or B. The dosages of the drugs were kept in the therapeutic range of 150–450 mg/day for clozapine and 400–800 mg/day for quetiapine.[11] Clozapine was started with 25 mg/day in two divided doses and increased by 25 mg/day, whereas quetiapine was started at 50 mg/day in two divided doses and increased by 50 mg/day. The minimum therapeutic dose in all the patients was reached within 2 weeks of starting the treatment. After this, patients were continued on the same dose for 4 weeks. At the end of 4 weeks, if the improvement was not adequate (<50% reduction in Positive and Negative Syndrome Scale [PANSS][12] score), the dose of the respective drug was further increased to the maximum permissible dose and the patients were re-assessed after 4 weeks and 8 weeks. Concomitant medications (like benzodiazepines for sleep disturbances, amitriptyline for hypersalivation, etc.) were permitted wherever required, and it was documented. Patients having serious adverse drug reaction were dropped from the study and managed as per the standard guidelines. Each patient’s sociodemographic and clinical variables were recorded on prescribed Performa designed specifically for the study.

**Outcomes**

Physical examination, body weight, height, QTC interval on electrocardiogram, blood chemistry, and complete hemogram were carried out at the baseline, 2nd week and thereafter every 4th week. In addition, total leucocyte count, differential leucocyte count, platelet count, absolute neutrophil count were done on a weekly basis for patients receiving clozapine. To ensure compliance in outpatients, a family member was entrusted to supervise the intake of the drug in their presence. In addition, the empty strips of medicines were shown to doctors during follow-up visits.

Patient’s clinical status was assessed with BPRS[13] and CGIs[14] at baseline and PANSS[15] at baseline, 2, 6, 10, and 14 weeks. Side effects were assessed using the Glasgow Antipsychotic Side Effect Rating Scale (GASS)[16] at baseline and thereafter at 2, 6, 10, and 14 weeks.

**Statistical method**

The statistical analysis included Chi-square test for qualitative data and ANOVA and MANOVA with
repeated measures for quantitative data. T-test was applied to compare individual assessments. Data were analyzed using SPSS version 17.0 (Version 17.0, IBM) and it was represented in mean and standard deviation (SD) where data were skewed, nonparametric test (Mann–Whitney test) was used. Significance level was $P < 0.05$.

**RESULTS**

A total of 72 patients were screened initially, of which 19 patients were excluded due to various reasons. Remaining 53 patients were enrolled in the study. Subsequently, 13 patients dropped out of the study after the first assessment (four in Group A; nine in Group B). From among the dropouts, six patients dropped out due to the lack of efficacy (one in Group A and five in Group B), three patients dropped out due to poor compliance (one in Group A and two in Group B), two patients dropped out due to intolerability of drug (one in each group) and two patients could not be contacted (one in each group). Finally, forty patients (twenty patients in each group) completed all assessments and were included in final analysis.

**Comparison between clozapine (Group A) and quetiapine (Group B) group on sociodemographic and clinical variables**

The patients in clozapine and quetiapine group did not differ significantly on sociodemographic variables, diagnosis, and clinical characteristics, i.e., total duration of illness, BPRS score, PANSS total scores, positive

| Table 1: Comparison between clozapine (Group A) and quetiapine (Group B) group on sociodemographic and clinical variables  |
| Variable | Group A ($n=20$) | Group B ($n=20$) | Significance ($P$) | 95% CI |
| --- | --- | --- | --- | --- |
| Age, mean (SD) | 39.40 (7.46) | 39.40 (6.82) | 1.000 | NA |
| Sex (%) | | | | |
| Male | 13 (65.0) | 14 (70.0) | 0.736 | NA |
| Female | 7 (35.0) | 6 (30.0) | | |
| Area (%) | | | | |
| Rural | 6 (30.0) | 7 (35.0) | 0.736 | NA |
| Urban | 14 (70.0) | 13 (65.0) | | |
| Education (%) | | | | |
| Below matric | 8 (40.0) | 7 (35.0) | 0.744 | NA |
| Matric and above | 12 (60.0) | 13 (65.0) | | |
| Occupation (%) | | | | |
| Working | 3 (15.0) | 2 (10.0) | 0.633 | NA |
| Nonworking | 17 (85.0) | 18 (90.0) | | |
| Income (%) | | | | |
| $<5000$ | 7 (35.0) | 10 (50.0) | 0.264 | NA |
| $5001-10,000$ | 2 (10.0) | 4 (20.0) | | |
| $>10,000$ | 11 (55.0) | 6 (30.0) | | |
| Family (%) | | | | |
| Nuclear | 12 (60.0) | 12 (60.0) | 1.000 | NA |
| Joint | 8 (40.0) | 8 (40.0) | | |
| Marital status | | | | |
| Single | 8 (40.0) | 8 (40.0) | 1.000 | NA |
| Ever-married | 12 (60.0) | 12 (60.0) | | |
| Diagnosis (%) | | | | |
| F20.0 | 10 (50.0) | 14 (70.0) | 0.611 | NA |
| F20.1 | 2 (10.0) | 1 (5.0) | | |
| F20.2 | 1 (5.0) | 1 (5.0) | | |
| F20.3 | 7 (35.0) | 4 (20.0) | | |
| Total duration of illness (years) | 14.35 (3.91) | 13.80 (3.89) | 0.658 | $-1.95$ |
| BPRS | 58.75 (3.96) | 58.20 (5.00) | 0.702 | $-3.44$ |
| CGI (severity of illness) | 4.95 (0.22) | 4.80 (0.41) | 0.162 | $-0.064$ |
| PANSS positive symptoms | 26.00 (3.08) | 24.05 (4.30) | 0.107 | $-4.43$ |
| PANSS negative symptoms | 26.65 (3.76) | 26.00 (4.18) | 0.608 | $-3.195$ |
| PANSS general psychopathology symptoms | 52.90 (5.79) | 51.35 (8.24) | 0.217 | $-2.546$ |
| PANSS total | 105.45 (8.57) | 101.30 (12.06) | 0.814 | $-0.953$ |
| GASS | 3.20 (1.36) | 3.30 (1.30) | | |

CI – Confidence interval; BPRS – Brief Psychiatric Rating Scale; CGI – Clinical global impression; PANSS – Positive and Negative Syndrome Scale; GASS – Glasgow Antipsychotic Side-effect Rating Scale; SD – Standard deviation; NA – Not applicable
subscale scores, negative subscale scores, and general psychopathology subscale scores and CGI (severity of illness) and GASS score [Table 1].

**Drug efficacy**

Twenty percent reduction in psychopathology score was taken as a response in the study. In our study, six patients (30%) in clozapine group and three patients (15%) in quetiapine group showed a response (>20% reduction in PANSS from baseline) at the endpoint, i.e., 14 weeks. However, the difference between the two groups was not significant ($P = 0.256$).

**Comparison of Positive and Negative Syndrome Scale scores of two groups across assessments**

On within group analysis while there was statistically significant improvement in positive, negative, general subscale, and total score of PANSS in clozapine group, with regards to quetiapine such improvement, was present only in negative subscale of PANSS [Table 2].

**Change in Positive and Negative Syndrome Scale scores for clozapine and quetiapine group**

At the end of 14 weeks, the patients assigned to clozapine had significantly greater reductions in the PANSS total score (mean = 14.45, SD = 10.39) than the patients assigned to quetiapine (mean = 4.15, SD = 10.71, $P = 0.004$). A similar significantly greater reduction in clozapine group was seen on the PANSS positive subscale and PANSS general psychopathology subscale. However, on the negative subscale of PANSS, there was a significant reduction with both clozapine and quetiapine and the difference between two drugs was not significant [Tables 2 and 3].

**Comparison of the side-effects in clozapine (Group A) and quetiapine (Group B) group**

There was statistically significant increase in GASS score at 6, 10, and 14 weeks from baseline in both groups [Tables 4 and 5]. However, while comparing the two drugs, a statistically significant difference was seen at week 6, 10, and 14 and quetiapine was found to be superior to clozapine in terms of side-effect profile. The most common side effects observed in clozapine group were increased sleepiness/sedation (63%), feeling drugged (60%), drooling of saliva at night (45%) and dizziness (35%) and weight gain (45%). The most common side effects noted in quetiapine group were dry mouth (50%), difficulty in passing urine (45%), sleepiness/sedation (35%), dizziness (30%), and weight gain (20%).

**DISCUSSION**

To the best of our knowledge, this is the first Indian study carried out to compare the efficacy and tolerability of clozapine and quetiapine in TRS. Forty patients who completed all four assessments were included in the final analysis. The two groups were comparable at baseline on sociodemographic and clinical variables. The mean dose of clozapine was 322.50 mg/day, and quetiapine was 790.0 mg/day.

**Clozapine group**

In this study, 6 (30%) patients in clozapine group showed response. This finding concurs with the multi-centre study conducted by Kane et al. which established clozapine as preferred drug for TRS and another large randomized double-blind comparative study of clozapine and haloperidol in patients of refractory schizophrenia in which superior improvement was
were defined as PANSS responders compared to 38% improvement could be the inclusion of mildly ill patients in our study were moderately ill (score of 4 or more on CGI) and lower degree of treatment resistance. Findings of this study are also inconsistent with the studies.

The superiority of clozapine over typical and atypical antipsychotics has been reported in some systematic reviews and meta-analysis. However, studies comparing clozapine with quetiapine were not included in these. Furthermore, there was a high degree of heterogeneity in terms of duration of the study, dosage of drugs used, level of resistance to previous treatment and financial support from a drug company among various studies included in these systematic reviews and meta-analysis, and hence it may not be appropriate to include these studies in a meta-analysis.

The response rate of 30% with clozapine in this study is somewhat similar to these two studies.

In this study, the difference between clozapine and quetiapine in terms of response rate was not statistically significant which can be attributed to a smaller sample size of this study.

Patients assigned to clozapine had significantly greater reductions on positive symptoms, general psychopathology and total PANSS score than the patients assigned to quetiapine. However, there was no significant difference between the two groups so far as reduction in negative symptoms was concerned; both drugs produced significant improvement in negative symptoms from the baseline assessment. These results are consistent with Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Phase 2 investigations, where patients assigned to clozapine had significant reductions in the PANSS total score and PANSS general psychopathology subscale than the patients assigned to quetiapine. Reductions in positive and negative subscale scores in clozapine group were greater than quetiapine, but it was not statistically significant in that study.[24] Another noncommercially funded, pragmatic, open, multisite, and randomized controlled trial comparing clozapine with other SGA (including quetiapine) showed that the improvement seen in clozapine group was significantly higher in comparison to SGA group at 12, 26, and 52 weeks, although authors did not publish results for the different SGA.[25]

However, findings of this study should be interpreted carefully because clozapine is associated with sedation, hyper-salivation, orthostatic hypertension and metabolic side effects leading to poor tolerability. Other serious side effects such as agranulocytosis, seizure, and myocarditis have been reported in the literature. Further important limitation arises from the need of slow titration and weekly blood counts which are laborious. In addition, a significant proportion of TRS population is nonresponder to even clozapine.[5] Thus, there is still a prospect for using other molecules when clozapine is ineffective or intolerable though uncertainty exists regarding which molecule should be used in such a scenario.

| Table 4: Comparison on Glasgow Antipsychotic Side-effect Scale between two groups (Group A - clozapine, Group B - quetiapine) |
|----------------------------------|--------------|----------------|-----|-----|
| Assessment | Mean (SD) | Significance (P) | 95% CI |
| Group A | Group B | Lower | Upper |
| Baseline | 3.20 (1.36) | 3.30 (1.30) | 0.814 | -0.953 | 0.753 |
| 6 weeks | 12.50 (3.40) | 7.25 (2.12) | <0.001* | 3.437 | 7.063 |
| 10 weeks | 14.20 (2.70) | 9.55 (1.57) | <0.001* | 3.233 | 6.067 |
| 14 weeks | 14.80 (3.74) | 10.65 (1.95) | <0.001* | 2.241 | 6.059 |

*Skewed data, P value calculated with nonparametric tests.
SD – Standard deviation; CI – Confidence interval

| Table 5: Effects of clozapine (Group A) and quetiapine (Group B) across assessments on Glasgow Antipsychotic Side-effect Rating Scale |
|----------------------------------|----------------|-----|-----|
| Group | Baseline versus 6 weeks | Baseline versus 10 weeks | Baseline versus 14 weeks |
| Group A | <0.001 | <0.001 | <0.001 |
| Group B | <0.001 | <0.001 | <0.001 |

Skewed data, P value calculated with nonparametric tests.
Negative symptoms predominate major portion of the course of illness and account for much of the long-term morbidity and poor functional outcome of patients with schizophrenia. In such a scenario, quetiapine can be considered as a viable alternative as it showed a response in 15% of patients and was associated with significant improvement in negative symptoms. In fact, a metaanalysis conducted by Cochrane Schizophrenia group has found quetiapine to be more efficacious than clozapine on the negative symptom subscore.

The current study found that quetiapine was better so far as side effects of the two drugs were concerned as reflected by the GASS score. In addition, the side effects of both the drugs were mild in severity as only one patient in each group had dropped out due to side effects. However, the retention rate was better in the clozapine group as 4 patients dropped out from this group as compared to 9 patients in the other group. Clozapine was associated with sedation, hyper-salivation, and weight gain in greater proportion of the patients, whereas quetiapine caused anticholinergic side effects (dry mouth, difficulty in passing urine, etc.) in more number of patients and this finding are consistent with previous CATIE trials. The current study, in fact, showed greater anticholinergic side effects due to quetiapine compared to a previous industry-sponsored study.

CONCLUSION

Clozapine is still a good choice in TRS, and it was found to be more effective than quetiapine. However, clozapine was associated with greater side effects than quetiapine. Quetiapine, on the other hand, was also effective and equivalent to clozapine in the reduction of negative symptoms. Thus quetiapine might be a better choice in cases of TRS with predominant negative symptomatology, especially in instances where clozapine is ineffective or cannot be used.

Acknowledgments

Patients who participated in the study, all faculty of the Department of Psychiatry, GMCH, Chandigarh, India.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

REFERENCES

1. Whiteford HA, Ferrari AJ, Degenhardt L, Feigin V, Vos T. The global burden of mental, neurological and substance use disorders: An analysis from the Global Burden of Disease Study 2010. PLoS One 2015;10:e0116820.
2. Conley RR, Kelly DL. Management of treatment resistance in schizophrenia. Biol Psychiatry 2001;50:898-911.
3. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-96.
4. Wahlbeck K, Cheine M, Essali A, Adams C. Evidence of clozapine’s effectiveness in schizophrenia: A systematic review and meta-analysis of randomized trials. Am J Psychiatry 1999;156:990-9.
5. Remington G, Saha A, Chong SA, Shammi C. Augmentation strategies in clozapine-resistant schizophrenia. CNS Drugs 2005;19:943-72.
6. Nemeroff CB, Kinkead B, Goldstein J. Quetiapine: Preclinical studies, pharmacokinetics, drug interactions, and dosing. J Clin Psychiatry 2002;63 Suppl 13:5-11.
7. Buckley PF, Goldstein JM, Emsley RA. Efficacy and tolerability of quetiapine in poorly responsive, chronic schizophrenia. Schizophr Res 2004;66:143-50.
8. World Health Organization. The ICD-10 Classification of Mental and Behavioural disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva: World Health Organisation; 2006.
9. Williams JR. The Declaration of Helsinki and public health. Bull World Health Organ 2008;86:650-2.
10. Indian Council of Medical Research. Ethical guidelines for biomedical research on human participants. New Delhi: Indian Council of Medical Research; 2006.
11. Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004;161 2 Suppl:1-56.
12. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76.
13. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep 1962;10:799-812.
14. Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville: US Department of Health and Human Services Publication; 1976.
15. Waddell L, Taylor M. A new self-rating scale for detecting atypical or second-generation antipsychotic side effects. J Psychopharmacol 2008;22:238-43.
16. Rosenheck R, Cramer J, Xu W, Thomas J, Henderson W, Frisman L, et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. N Engl J Med 1997;337:809-15.
17. Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: A review and meta-analysis of randomized trials. Am J Psychiatry 2001;158:518-26.
18. Tuunainen A, Wahlbeck K, Gilbody S. Newer atypical antipsychotic medication in comparison to clozapine: A systematic review of randomized trials. Schizophr Res 2002;56:1-10.
19. Moncrieff J. Clozapine v. conventional antipsychotic drugs for treatment-resistant schizophrenia: A re-examination. Br J Psychiatry 2003;183:161-6.
20. Sacchetti E, Panariello A, Regini C, Valsecchi P. Quetiapine in hospitalized patients with schizophrenia refractory to treatment with first-generation antipsychotics: A 4-week, flexible-dose, single-blind, exploratory, pilot trial. Schizophr
Kumar, et al.: Clozapine versus quetiapine in TRS

21. Buchanan RW, Breier A, Kirkpatrick B, Ball F, Carpenter WT Jr. Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am J Psychiatry 1998;155:751-60.

22. Wahlbeck K, Cheine M, Tuisku K, Ahokas A, Joffe G, Rimón R. Risperidone versus clozapine in treatment-resistant schizophrenia: A randomized pilot study. Prog Neuropsychopharmacol Biol Psychiatry 2000;24:911-22.

23. Hong CJ, Chen JY, Chiu HJ, Sim CB. A double-blind comparative study of clozapine versus chlorpromazine on Chinese patients with treatment-refractory schizophrenia. Int Clin Psychopharmacol 1997;12:123-30.

24. McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006;163:600-10.

25. Lewis SW, Barnes TR, Davies L, Murray RM, Dunn G, Hayhurst KF, et al. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull 2006;32:715-23.

26. Stroup TS, Lieberman JA, McEvoy JP, Davis SM, Swartz MS, Keefe RS, et al. Results of phase 3 of the CATIE schizophrenia trial. Schizophr Res 2009;107:1-12.

27. Atkin K, Kendall F, Gould D, Freeman H, Liberman J, O’Sullivan D. Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland. Br J Psychiatry 1996;169:483-8.

28. Pacia SV, Devinsky O. Clozapine-related seizures: Experience with 5,629 patients. Neurology 1994;44:2247-9.

29. Haas SJ, Hill R, Krum H, Liew D, Tonkin A, Demos L, et al. Clozapine-associated myocarditis: A review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003. Drug Saf 2007;30:47-57.

30. Dold M, Leucht S. Pharmacotherapy of treatment-resistant schizophrenia: A clinical perspective. Evid Based Ment Health 2014;17:33-7.

31. Kirkpatrick B, Buchanan RW, Ross DE, Carpenter WT Jr. A separate disease within the syndrome of schizophrenia. Arch Gen Psychiatry 2001;58:165-71.

32. Milev P, Ho BC, Arndt S, Andreasen NC. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: A longitudinal first-episode study with 7-year follow-up. Am J Psychiatry 2005;162:495-506.

33. Kurtz MM, Moberg PJ, Ragland JD, Gur RC, Gur RE. Symptoms versus neurocognitive test performance as predictors of psychosocial status in schizophrenia: A 1- and 4-year prospective study. Schizophr Bull 2005;31:167-74.

34. Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmidt F, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 2009;166:152-63.

35. Mullen J, Jibson MD, Sweitzer D. A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: The quetiapine experience with safety and tolerability (QUEST) study. Clin Ther 2001;23:1839-54.